Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis

Tseng, Cheng‐Hao; Hsu, Yao‐Chun; Chen, Tzu‐Haw; Ji, Fanpu; Chen, I‐Sung; Tsai, Ying‐Nan; Hoang, Hai; Thủy, Lê Thị Thanh; Hosaka, Tetsuya; Sezaki, Hitomi; Borghi, John; Cheung, Ramsey; Enomoto, Masaru; Nguyen, Mindie H.

doi:10.1016/s2468-1253(20)30249-1

Cited by 87 publications

(105 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent international study including 19 centers from 6 countries or regions also revealed that TDF and ETV had a similar effect in the prevention of HCC in patients with CHB [69] . In the latest meta-analysis investigating 31 studies that enrolled 119,053 patients, the incidence of HCC was similar in patients with TDF or ETV treatment [70] . Taking these lines of evidence together and unless we could have a large-scale head-to-head comparison study, the preventive effects for HBV-related HCC of first-line NAs remain unsettled.…”

Section: Anti-hbv Therapymentioning

confidence: 99%

Prevention of hepatitis B virus-related hepatocellular carcinoma

Kao¹

2021

View full text Add to dashboard Cite

Section: Anti-hbv Therapymentioning

confidence: 99%

Prevention of hepatitis B virus-related hepatocellular carcinoma

Kao¹

2021

View full text Add to dashboard Cite

“…Very few high‐quality studies have shown the opposite direction of favoring ETV over TDF. Even the meta‐analyses that showed no statistically significant difference in HCC risk between the two drugs indicated a lower hazard ratio (around 0.8) for HCC with TDF compared with ETV 64 …”

Section: Different Effects Of Anti‐hbv Drugs On Hcc Riskmentioning

confidence: 97%

“…Even the meta-analyses that showed no statistically significant difference in HCC risk between the two drugs indicated a lower hazard ratio (around 0.8) for HCC with TDF compared with ETV. 64 Tenofovir alafenamide (TAF) has been recently added to one of the first line agents for CHB treatment by international guidelines. 16,17 Pooled data from global and Chinese phase 3 trials consisting of more than 1600 patients, TAF treatment appeared to have a lower risk of HCC than TDF treatment, especially with early ALT normalization during treatment, although the difference did not reach statistical significance.…”

Section: Different Effects Of Anti-hbv Drugs On Hcc Riskmentioning

confidence: 99%

Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies

Choi

Lim

2021

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Over the past decades, marked advancement has been made in the prevention and treatment of hepatitis B virus (HBV) infection. Due to highly effective antiviral therapies for chronic hepatitis B (CHB), long-term clinical outcomes in patients with CHB has also been dramatically improved. However, current antiviral therapies for CHB cannot completely abolish the risk of hepatocellular carcinoma (HCC). In addition, current treatment guidelines for CHB should be interpreted with caution given that HBV-associated hepatocarcinogenesis could be underway in patients who are not eligible for antiviral therapies by current guidelines. Therefore, efforts to reconcile treatment guidelines with recent clinical evidence should be made for reducing further development of HCC. In this article, we review the secondary prevention of HBV-related HCC with current antiviral therapies.

show abstract

“…However, comparison of efficacy between ETV and TDF is still controversial. It is reported in a large proportion of studies including comparative studies and meta-analysis that TDF and ETV are comparable in treatment response, preventing occurrence of hepatocellular carcinoma and safety (20)(21)(22)(23)(24)(25)(26). A small number of studies suggest otherwise.…”

Section: Introductionmentioning

confidence: 99%

Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study

Yang

Cai

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Aim: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are equally recommended as the first-line antiviral treatments for chronic hepatitis B (CHB) at present. We aimed to compare the long-term efficacy and safety between ETV and TDF therapy in CHB patients who had not received nucleoside analog treatment.Method: In this single-center retrospective study, 414 patients who received ETV (290 patients) or TDF (124 patients) therapy at our center from January 2017 to May 2019 were included. To reduce the imbalance of baseline variables, propensity score matching (PSM) was employed to yield 124 pairs of patients at a ratio of 1:1 based on the treatment regimen.Result: After PSM, the cumulative rate of patients who achieved complete virological response (CVR) was not different by drug therapy at each inspection time (1, 3, 6, 12, 18, and 24 months). Subgroup analysis on HBeAg status and level of HBV DNA demonstrated that evolution of proportion of achieving CVR was not significantly different between groups. Despite the insignificant incidence of HBsAg seroclearance in either group, patients in TDF group achieved higher on-treatment HBsAg decline at each inspection time (1, 3, 6, 9, 12, 18, and 24 months), 0.39, 0.51, 0.61, 0.64, 0.68, 0.76, and 0.91 log IU/mL, respectively; while the corresponding reduction were 0.27, 0.37, 0.40, 0.45, 0.48, 0.55, and 0.66 log IU/mL in ETV group (p < 0.05). In subgroup analysis, we found that the significant difference still existed in patients with high baseline HBsAg level (>3 log IU/mL). Additionally, the proportion of patients who achieved on-treatment HBsAg decline >1 log IU/mL in TDF and ETV group was 33.3 and 17.1% (p < 0.01) at the 12th month, 44.4 and 29.5% (p = 0.03) at the 24th month, respectively. Mean increase in serum creatinine from baseline was 0.10 and 0.08 mg/dL in TDF and ETV group (p = 0.11), with no patient experienced acute kidney injury.Conclusions: TDF has higher potency in reducing HBsAg than ETV in this study. Considering the effect still existed in patients with high HBsAg level (>3 log IU/mL), TDF might be a superior therapeutic regimen combining with its relatively safety.

show abstract

Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis

Cited by 87 publications

References 44 publications

Prevention of hepatitis B virus-related hepatocellular carcinoma

Prevention of hepatitis B virus-related hepatocellular carcinoma

Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies

Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study

Contact Info

Product

Resources

About